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Abstract
Introduction: Fibromyalgia is a chronic pain syndrome with unknown etiology. Recent studies have shown some 
evidence demonstrating that oxidative stress may have a role in the pathophysiology of fibromyalgia. However, it is still 
not clear whether oxidative stress is the cause or the effect of the abnormalities documented in fibromyalgia. 
Furthermore, the role of mitochondria in the redox imbalance reported in fibromyalgia also is controversial. We 
undertook this study to investigate the role of mitochondrial dysfunction, oxidative stress, and mitophagy in 
fibromyalgia.
Methods: We studied 20 patients (2 male, 18 female patients) from the database of the Sevillian Fibromyalgia 
Association and 10 healthy controls. We evaluated mitochondrial function in blood mononuclear cells from 
fibromyalgia patients measuring, coenzyme Q10 levels with high-performance liquid chromatography (HPLC), and 
mitochondrial membrane potential with flow cytometry. Oxidative stress was determined by measuring mitochondrial 
superoxide production with MitoSOX™ and lipid peroxidation in blood mononuclear cells and plasma from 
fibromyalgia patients. Autophagy activation was evaluated by quantifying the fluorescence intensity of LysoTracker™ 
Red staining of blood mononuclear cells. Mitophagy was confirmed by measuring citrate synthase activity and 
electron microscopy examination of blood mononuclear cells.
Results: We found reduced levels of coenzyme Q10, decreased mitochondrial membrane potential, increased levels of 
mitochondrial superoxide in blood mononuclear cells, and increased levels of lipid peroxidation in both blood 
mononuclear cells and plasma from fibromyalgia patients. Mitochondrial dysfunction was also associated with 
increased expression of autophagic genes and the elimination of dysfunctional mitochondria with mitophagy.
Conclusions: These findings may support the role of oxidative stress and mitophagy in the pathophysiology of 
fibromyalgia.
Introduction
Fibromyalgia (FM) is a common chronic pain syndrome
accompanied by other symptoms such as fatigue, headache,
sleep disturbances, and depression. It is diagnosed accord-
ing to the classification criteria established by the American
College of Rheumatology (ACR) [1]. Despite being a com-
mon disorder that affects at least 5 million individuals in the
United States [2], its pathogenic mechanism remains elu-
sive. Recently oxidative stress markers were proposed as a
relevant event in the pathogenesis of this disorder [3,4].
Previously, we detected decreased coenzyme Q10 (CoQ10)
levels and increased reactive oxygen species (ROS) produc-
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Page 2 of 11tion in blood mononuclear cells of FM patients, providing
direct evidence of increased oxidative stress at the cellular
level [5]. CoQ10 plays a crucial role in cellular metabolism,
acting as an electron carrier between complexes I and II and
complex III of the mitochondrial respiratory chain. CoQ10
also has been reported to play an important role in the regu-
lation of uncoupling proteins, mitochondrial permeability
transition pore, β-oxidation of fatty acids, and the nucle-
otide-biosynthesis pathway [6]. Moreover, CoQ10 levels
have been suggested to be useful as a mitochondrial-dys-
function marker [7]. CoQ10 deficiency induces decreased
activities of complex II + III, complex III and complex IV,
reduced expression of mitochondrial proteins involved in
oxidative phosphorylation, decreased mitochondrial mem-
brane potential, increased production of reactive oxygen
species (ROS), activation of mitochondrial permeability
transition (MPT), mitophagy of dysfunctional mitochon-
dria, and reduced growth rates [8,9].
The purpose of the present work was to assess the mito-
chondrial dysfunction in blood mononuclear cells of FM
patients and to elucidate whether mitochondrial disturbance
was involved in the pathophysiology of oxidative stress
present in FM.
Materials and methods
Patients and controls
The study was performed with the informed consent of all
participants and the approval of the local ethical committee.
We studied 20 patients (two male and 18 female patients)
recruited from the database of the Sevillian Fibromyalgia
Association (AFIBROSE) and 10 healthy controls (two
male and eight female patients). The diagnosis of FM was
established by an experienced rheumatologist according to
ACR criteria [1]. All patients and controls had not taken
any drug or vitamin/nutritional supplement during a 15-day
period before the collection of the blood samples.
Blood mononuclear cells cultures
Peripheral blood mononuclear cells (BMCs) were purified
from heparinized blood with isopycnic centrifugation by
using Histopaque-1119 and Histopaque-1077 (Sigma
Chemical Co., St. Louis, MO, USA). BMCs were cultured
at 37°C in a 5% CO2 atmosphere in RPMI-1640 medium
supplemented with L-glutamine, an antibiotic/antimycotic
solution (Sigma Chemical Co.), and 10% fetal bovine
serum.
Measurement of CoQ10 levels
CoQ10 contents in BMCs were analysed with HPLC (Beck-
man Coulter, Brea, CA, USA; 166-126 HPLC) with ultravi-
olet detection (275 nm), according to the method of
Montero and colleagues
Mitochondrial membrane potential (ΔΨm)
BMCs were cultured in six-well plates (35-mm diameter
well) until confluence. Mitotracker Red CMXRos (Invitro-
gen/Molecular Probes, Eugene, OR, USA) 100 nmol/L was
added and incubated for 30 min. Then cells were washed
and analyzed with flow cytometry.
Mitochondrial ROS production
Mitochondrial ROS generation in BMCs was assessed with
MitoSOX™ (Invitrogen/Molecular Probes, Eugene, OR,
USA) incubated with 1 μmol/L MitoSox for 30 min at 37°C
and washed twice with PBS. Cells were analyzed with flow
cytometry. To assay ROS production with antioxidants,
mononuclear cells were incubated 24 h with 10 μmol/L
CoQ10, 30 μmol/L α-tocopherol (α-toc), and 10 mmol/L N-
acetylcisteine (N-Acet; Sigma Chemical Co.).
Lipid peroxidation
TBARS (thiobarbituric acid reactive substances) levels in
plasma were determined by a method based on the reaction
with thiobarbituric acid at 90-100°C. Lipid peroxidation in
cells was determined by analyzing the accumulation of
lipoperoxides with a commercial kit from Cayman Chemi-
cal (Ann Arbor, Michigan, USA). TBARS are expressed in
terms of malondialdehyde (MDA) levels. In these assays,
an MDA standard is used to construct a standard curve
against which unknown samples can be plotted.
Loading of Lysotracker Red
BMCs were cultured in RPMI-1640 medium.
LysoTracker™ red (Invitrogen/Molecular Probes) (100
nmol/L), a cell-permeant fluorophore that typically concen-
trate in acidic vacuoles, was added to isolated BMCs from
control and FM patients. After 30 min, cells were washed,
and the red fluorescence of LysoTracker was quantified
with flow cytometry.
Real-time PCR
The expression of both MAP-LC3 and BECLIN 1 genes in
BMCs was analyzed with SYBR Green quantitative PCR
by using mRNA extracts and primers. Real-time BECLIN 1
primers 5'-GGA TGG ATG TGG AGA AAG GCA AG-3'
(forward primer) and 5'-TGA GGA CAC CCA AGC AAG
ACC-3' (reverse primer) amplify a sequence of 152 nucle-
otides. Human MAP-LC3 primers 5'-GCC TTC TTC CTG
CTG GTG AAC-3' (forward primer) and 5'-AGC CGT
CCT CGT CTT TCT CC-3' (reverse primer) amplify a
sequence of 91 nucleotides. Actin was used as a housekeep-
ing control gene.
Measurement of citrate synthase activity
The specific activity of citrate synthase in whole-cell
extracts prepared from BMCs was measured at 412 nm
minus 360 nm (13.6 mmol/L/cm) by using 5,5-dithio-bis(2-
nitrobenzoic acid) to detect free sulfhydryl groups in coen-
zyme A, as described previously [11].
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BMCs were fixed for 15 min with 2% glutaraldehyde in
culture medium and then for 30 min in 2% glutaraldehyde-
0.1 mol/L NaCacodylate/HCl, pH 7.4. Samples were pro-
cessed as described previously [9]. Observations were per-
formed on a Philips CM-10 transmission electron
microscope.
Statistical analysis
All results are expressed as mean ± SD, unless stated other-
wise. The unpaired Student's t test was used to evaluate the
significance of differences between groups. Statistical anal-
yses included Pearson's correlations between CoQ10 levels
and autophagic gene expression levels. The P values less
than 0.05 were considered significant.
Results
Mitochondrial dysfunction in FM
The mean age of patients was 50.8 ± 8.6 years for the FM
group and 49.1 ± 9.8 years for the control group. The mean
duration of symptoms in the FM group was 13.65 ± 9.19
years. The mean tender points in the FM group were 14.9 ±
3.1 points. The most prominent features of these FM
patients were pain and stiffness. They were sedentary peo-
ple. Routine laboratory tests yielded normal results for glu-
cose, urea, uric acid, total protein, creatinine, aspartate
aminotransferase, alanine aminotransferase, cholesterol,
and triglycerides (data not shown).
CoQ10 levels, determined in BMCs isolated from 20 FM
patients, were found to be about 40% lower than those in
control cells (Figure 1a). To examine further the mitochon-
drial dysfunction in BMCs from FM patients, we deter-
mined the mitochondrial membrane potential (ΔΨm) with
flow cytometry. Mitochondrial membrane potential was
significantly reduced by about 36% in BMCs from FM
patients (Figure 1b).
Oxidative stress in FM
Oxidative stress has been proposed as a relevant event in
the pathogenesis of FM [3,12]. In a previous work, we
showed the presence of high levels of ROS production in
the BMCs of FM patients [5]. To assess the mitochondrial
origin of ROS production, BMCs from FM patients and
controls were exposed to MitoSOX™, a red mitochondrial
superoxide indicator. Quantification of ROS production
with flow-cytometry analysis demonstrated a significant
increase in ROS production in mitochondria of BMCs from
FM patients with respect to control (Figure 2a). Addition-
ally, we determined lipid peroxidation as a marker of oxida-
tive stress-induced membrane damage by mitochondrial
ROS in BMCs and plasma from FM patients. On average,
FM patients showed a higher level of lipid peroxidation in
both cells and plasma with respect to control subjects (Fig-
ure 2b and 2c).
Further to examine the role of ROS generation in FM,
BMCs of one representative patient were incubated with
three antioxidants, CoQ10, α-toc, and N-Acet, and mito-
chondrial ROS production was examined (Figure 3). Only
lipophilic antioxidants, CoQ10 and α-toc, significantly
attenuated ROS production.
Autophagy in BMC from FM patients
Recently, it was demonstrated that CoQ10-deficient fibro-
blasts exhibit increased levels of lysosomal markers (β-
galactosidase, cathepsin, LC3, and Lyso Tracker) and
enhanced expression of autophagic genes at both transcrip-
tional and translational levels, indicating the presence of
autophagy [9]. To verify that CoQ10 deficiency also induces
activation of autophagy in BMCs from FM patients, we
first quantified levels of acidic vacuoles in BMCs by using
Lysotracker fluorescence and flow-cytometry analysis.
Acidic vacuoles were significantly increased in patient
BMCs with respect to controls (Figure 4a). To elucidate
whether autophagy in CoQ10-deficient BMCs could be mit-
igated by restoring mitochondrial functionality by CoQ10
supplementation, we cultured both control and patient
BMCs in the presence of CoQ10 (100 μmol/L) for 24 hours
and analyzed them by Lysotracker fluorescence. As is
shown in Figure 4b, CoQ10 supplementation drastically
reduced the intensity of Lysotracker fluorescence, indicat-
ing a reduction in lysosomal activity after CoQ10 treatment.
In addition, we analyzed the expression of genes involved
in autophagic processes, such as BECLIN 1 and MAP-LC3.
Figure 5a and 5b show that autophagic genes were overex-
pressed in BMCs of five of the eight patients tested as com-
pared with controls. FM patients with increased expression
of autophagic genes were those with a most pronounced
CoQ10 deficiency (P3, P5, P6, P7, P8). A negative correla-
tion was seen between the expression of autophagic genes
and CoQ10 levels (r = -0.80, P < 0.01 for BECLIN 1, and r =
-0.76, P < 0.001 for MAP-LC3) (Figure 5c).
To determine whether autophagy was specific for mito-
chondria, we first examined mitochondrial mass in BMCs
derived from FM patients. BMC extracts were prepared
from control and FM patients and analyzed for citrate syn-
thase activity. Citrate synthase is a mitochondrial matrix
protein whose activity has been shown to correlate well
with mitochondrial mass [13]. Figure 6a shows a statisti-
cally significant decrease in citrate synthase activity in
BMCs from FM patients compared with controls. The
reproducible reduction in citrate synthase activity indicates
a decrease in mitochondrial mass and suggests selective
degradation of mitochondria. To confirm the presence of
mitochondrial degradation or mitophagy in BMCs, we then
performed electron microscopy on control and patient
BMCs (Figure 6b and 6c. Figure 6c clearly shows the pres-
ence of autophagosomes in BMCs from a representative
Cordero et al. Arthritis Research & Therapy 2010, 12:R17
http://arthritis-research.com/content/12/1/R17
Page 4 of 11
Figure 1 Coenzyme Q10 levels and mitochondrial membrane potential (ΔΨm) in blood mononuclear cells (BMCs) from fibromyalgia (FM) 
patients and healthy control subjects. (a) CoQ10 levels were measured with high-performance liquid chromatography, as described in Materials 
and Methods. Data represent the mean ± SD of three separate experiments. (b) Mitochondrial membrane potential was analyzed in BMCs from con-
trol subjects and FM patients with flow cytometry, as described in Materials and Methods. Data represent the mean ± SD of three separate experiments. 
*P < 0.001 between controls and FM patients.
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Figure 2 Reactive oxygen species (ROS) production and lipid peroxidation in fibromyalgia (FM) patients. (a) ROS production was analyzed in 
BMCs from control subjects and FM patients with flow cytometry, as described in Materials and Methods. Lipid peroxidation (MDA levels) in blood 
mononuclear cells (BMCs) (b) and plasma (c) from control subjects and FM patients were determined as described in Materials and Methods. Data 
represent the mean ± SD of three separate experiments. *P < 0.001 between controls and FM patients.
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chondria. In early autophagosomes, it can clearly be
observed that mitochondria are being degraded.
Discussion
Mitochondria generate energy primarily in the form of the
electrochemical proton gradient, which fuels ATP produc-
tion, ion transport, and metabolism. Mitochondria are also
the major source of ROS. Both complexes I and III, along
with CoQ10, leak electrons to oxygen [14-17].
CoQ10deficiency has been associated with a variety of
human disorders, some of them caused by a direct defect of
CoQ10 biosynthesis genes or as a secondary consequence of
other diseases [18,19]. Recent findings show that CoQ10
deficiency alters mitochondrial function and mitochondrial
respiratory complex organization, leading to increased ROS
generation, activation of MPT, and increased autophagy of
dysfunctional mitochondria by mitophagy [8,9]. In the pres-
ent study, we found that CoQ10-deficient BMCs in FM
patients showed high levels of ROS production in mito-
chondria and increased levels of lipid peroxidation in both
cells and plasma. In this respect, high levels of lipid peroxi-
dation and protein carbonyls [20,21] and disturbances in the
homeostasis of platelet ATP have been observed in FM
patients [22]. The fact that CoQ10 and α-toc, two lipophilic
antioxidants, significantly reduced mitochondrial ROS pro-
duction, also suggests that ROS are produced in the lipo-
philic environment of mitochondrial membranes and that
CoQ10 deficiency may be involved in oxidative stress in
FM.
If oxidative damage plays a role in FM through the acti-
vation of MPT and mitophagy, then therapeutic strategies
that reduce ROS may ameliorate the pathologic process.
What is the relation between oxidative stress and FM symp-
toms? Recent studies showed that oxidative stress can cause
peripheral and central sensitization and alter nociception
[23], resulting in hyperalgesia mediated by both local and
spinal oxidant mechanisms. Furthermore, oxidative stress is
increased in patients with chronic-fatigue syndrome
[24,25]. Superoxide plays a major role in the development
of pain through direct peripheral sensitization, the release
of various cytokines (for example, TNF-α, IL-1β, and IL-
6), the formation of peroxynitrite (ONOO-), and PARP acti-
vation [23]. In addition, studies on depression, a typical
symptom in FM patients, have elucidated the possible link
between depression and lipid peroxidation [26]. Lipid per-
oxidation may play an important role in depression, and the
peroxidation-reducing effect of different selective serotonin
reuptake inhibitors in major depression was demonstrated
by Bilici and associates [27].
In addition, and supporting the role of mitochondrial dys-
function, BMCs of FM patients showed a decrease of 36%
of mitochondrial membrane potential (ΔΨm), possibly
reflecting a reduced electron flow and proton pumping
caused by CoQ deficiency. Interestingly, a positive correla-
tion between the content of CoQ10 in BMCs and skeletal
muscle [28,29] was demonstrated; therefore, CoQ10 defi-
ciency and mitochondrial dysfunction can also be present in
other cells and tissues in FM patients. Furthermore, changes
in the morphology and number of mitochondria have been
Figure 3 Effect of antioxidants on reactive oxygen species (ROS) generation. Blood mononuclear cells (BMCs) of representative fibromyalgia 
(FM) patients were treated with 10 μmol/L CoQ10, 30 μmol/L α-tocopherol (α-toc), and 10 μmol/L N-acetylcysteine (N-Acet) for 24 h. Data represent 
the mean ± SD of three separate experiments. *P < 0.001 between controls and FM patients; **P < 0.005 between the absence or presence of CoQ10 
and α-toc treatment.
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gesting the role of mitochondrial dysfunction in this disor-
der. CoQ deficiency, mitochondrial dysfunction, and cell
bioenergetics alteration could also explain the low muscular
and aerobic capacity observed in some groups of FM
patients [33,34].
It has been proposed that ROS damage can induce MPT
by opening of permeability transition pores in the mito-
chondrial inner membrane [35-37]. This, in turn, leads to a
simultaneous collapse of mitochondrial membrane potential
and the elimination of dysfunctional mitochondria by
mitophagy. Our results support this hypothesis, showing the
presence of mitophagy in BMCs of FM patients.
Autophagy is a regulated lysosomal pathway involved in
the degradation and recycling of cytoplasmic materials [38-
42]. During autophagy, cytoplasmic materials are seques-
tered into double-membraned vesicles, 'autophagosomes',
which then fuse with lysosomes to form autolysosomes, in
which degradation of cellular structures occurs. Many cel-
lular stresses can cause induction of autophagy, such as
endoplasmic reticulum stress, mitochondrial dysfunction,
or oxidative stress [42-44]. 'Mitophagy' was coined to
describe the selective removal of mitochondria by
autophagy during development and under pathologic condi-
tions [36,45]. In our work, biochemical analysis of citrate
synthase indicated a depletion of mitochondrial mass, sug-
Figure 4 Autophagic markers in blood mononuclear cells (BMCs) from fibromyalgia (FM) patients. (a) Quantification of acidic vacuoles in con-
trol and patient BMCs by LysoTracker fluorescence and flow-cytometry analysis. (b) Reduction of LysoTracker fluorescence in BMCs from FM patients 
under CoQ10 supplementation (100 μmol/L) for 24 h. Data represent the mean ± SD of three separate experiments. *P < 0.001 between controls and 
FM patients.
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Figure 5 Autophagic genes expression. Expression levels of BECLIN 1 (a) and MAP-LC3 (b) transcripts in blood mononuclear cells (BMCs) from con-
trol and fibromyalgia (FM) patients were assessed with real-time polymerase chain reaction (PCR), as described in Materials and Methods. Data repre-
sent the mean ± SD of three separate experiments. *P < 0.001 between controls and FM patients. (c) Correlation of CoQ10 levels and BECLIN 1 and MAP-
LC3 expression levels in BMCs from FM patients.
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Figure 6 Mitophagy in fibromylagia (FM) patients. (a) Decreased mitochondrial mass in blood mononuclear cells (BMCs) from FM patients. Citrate 
synthase specific activity in BMCs from control and FM patients was performed, as described in Materials and Methods. Data represent the mean ± SD 
of three separate experiments. *P < 0.001 between control and FM patients. (b) Ultrastructure of BMCs from FM patients. The control BMCs show mi-
tochondria with a typical ultrastructure. Autophagosomes with mitochondria (arrows) were present in BMCs from a representative FM patient (P6); 
Bar = 1 μm.
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in BMCs from FM patients. These results were confirmed
with electron microscopy that clearly shows autophago-
somes where mitochondria are being degraded. Autophagy
can be beneficial for the cells by eliminating dysfunctional
mitochondria, but massive autophagy can promote cell
injury [41] and may contribute to the pathophysiology of
FM.
Conclusions
Our study supports the hypothesis that CoQ10 deficiency,
oxidative stress, and extensive mitophagy can contribute to
cell-bioenergetics imbalance, compromising cell function-
ality. Abnormal BMC performance can promote oxidative
stress and may contribute to altered nociception in FM.
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